Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Summary

The purpose of this research study is to test the safety and tolerability of the combination treatment of the investigational drugs vorinostat and pembrolizumab, in combination with chemotherapy (temozolomide), and radiotherapy. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for use to treat a deadly skin cancer called melanoma and lung cancer and vorinostat to treat some forms of blood and lymph node cancers. However, both vorinostat and pembrolizumab are considered investigational drugs in this study because they are not approved for treatment of glioblastoma.

Timeline

Start

2018-03-16

Primary completion

2021-10-18

Completion

2023-06-28

Drugs

Indications